Kentaro Yoshimatsu
Fondateur chez Rin Institute, Inc.
Postes actifs de Kentaro Yoshimatsu
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Anaeropharma Science, Inc.
 Anaeropharma Science, Inc. BiotechnologyHealth Technology Anaeropharma Science, Inc. operates as a holding company that engages in the research and development of therapeutics to target hypoxic environment in solid cancers. It develops bifidobacterium technologies to create anti-cancer drugs. The firm's bifidobacterium therapeutics accumulates to the solid tumor when intravenously injected. The company was founded by Minoru Fujimori and Shunichiro Taniguchi on August 9, 2004 and is headquartered in Tokyo, Japan. | Directeur/Membre du Conseil | - | - |
Rin Institute, Inc.
 Rin Institute, Inc. Pharmaceuticals: MajorHealth Technology Rin Institute, Inc. is a company based in Tokyo, Japan that was founded in 2016 by Kentaro Yoshimatsu. The Japanese company's website simply states that it is "just another WordPress site." | Directeur/Membre du Conseil | 21/01/2016 | - |
| Fondateur | 21/01/2016 | - | |
| President | 21/01/2016 | - |
Historique de carrière de Kentaro Yoshimatsu
Anciens postes connus de Kentaro Yoshimatsu
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| EISAI CO., LTD. | Directeur Technique/Scientifique/R&D | 07/01/2010 | 30/09/2011 |
| Corporate Officer/Principal | 07/01/2010 | 16/09/2010 | |
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | President | 06/07/2011 | - |
Formation de Kentaro Yoshimatsu
| University of Tokyo | Doctorate Degree |
Statistiques
Internationale
| Japon | 5 |
| Etats-Unis | 2 |
Opérationnelle
| President | 2 |
| Director/Board Member | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| EISAI CO., LTD. | Health Technology |
| Entreprise privées | 3 |
|---|---|
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
Anaeropharma Science, Inc.
Anaeropharma Science, Inc. BiotechnologyHealth Technology Anaeropharma Science, Inc. operates as a holding company that engages in the research and development of therapeutics to target hypoxic environment in solid cancers. It develops bifidobacterium technologies to create anti-cancer drugs. The firm's bifidobacterium therapeutics accumulates to the solid tumor when intravenously injected. The company was founded by Minoru Fujimori and Shunichiro Taniguchi on August 9, 2004 and is headquartered in Tokyo, Japan. | Health Technology |
Rin Institute, Inc.
Rin Institute, Inc. Pharmaceuticals: MajorHealth Technology Rin Institute, Inc. is a company based in Tokyo, Japan that was founded in 2016 by Kentaro Yoshimatsu. The Japanese company's website simply states that it is "just another WordPress site." | Health Technology |
- Bourse
- Insiders
- Kentaro Yoshimatsu
- Expérience
